FDA panel to Forest on new use for heart drug: thumbs down – Federal health advisers on Monday unanimously rejected a new use of Forest Laboratories’ hypertension drug for patients at risk of heart failure. The Food and Drug Administration’s outside panel of heart specialists voted 8-0 against approving Bystolic to prevent death or hospitalization caused by heart failure, according to an agency spokeswoman….more
Withdrawal rates, Oxycontin, and selective publication of details. Sigh, Purdue.
Vivus’ new erectile dysfunction drug: fast results – Vivus Inc. on Monday reported positive test results for its erectile dysfunctional drug candidate avanafil, saying most men who took the drug were able to have sex within 15 minutes…more
Vertex lost less than $650 million in 2009. Well, that’s a relief!
The Medicines Company cutting 10% of workforce. Ouch.
Virtual Preceptorships. Great eLearning+Clinical understanding+Pharma training expertise. Our vendor/partners have that. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
JUST FOR FUN
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
Leave a Reply